Department of Pancreato-Biliary Surgery, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China.
Department of Gastrointestinal Surgery, Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, PR China.
Cancer Med. 2023 Jan;12(1):824-836. doi: 10.1002/cam4.4897. Epub 2022 May 29.
Hippocalcin-like 1 (HPCAL1) is involved in the development of several cancer types. However, our understanding of the HPCAL1 activity in cholangiocarcinoma (CCA) remains limited.
Two microarray datasets were used to screen for differentially expressed genes (DEGs) involved in the development of CCA. The Cancer Genome Atlas (TCGA)/Gene Expression Omnibus (GEO) database was integrated to determine the prognostic significance of DEGs in CCA. The association between clinical characteristics and HPCAL1 expression levels was initially explored to assess the clinical profile of CCA. The prognostic value of HPCAL1 overexpression in the validation cohort was analyzed, followed by Gene Ontology (GO) term analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of HPCAL1.
Three upregulated genes and 10 downregulated genes were detected from two microarray-based screenings. High expression of HPCAL1 as a poor prognostic factor of CCA was validated using TCGA/GEO integrated database and our database. Univariate and multivariate analyses along with Kaplan-Meier survival analysis showed that high HPCAL1 expression was an independent factor affecting the overall survival and relapse-free survival in patients with CCA. The high expression of HPCAL1 was significantly associated with cancer antigen 125 (CA-125) levels, number of tumors, lymph node invasion, and TNM stage. Analysis of the enriched GO terms and KEGG pathways revealed that the high expression of HPCAL1 was involved in the critical biological processes and molecular pathways, including modulation by a host of symbiont processes, the clathrin coat, actinin binding, and Rap1 signaling pathways.
HPCAL1 was enriched in CCA in our study and has the potential to be applied in the identification of patients with CCA with an unfavorable prognosis.
类海兔钙结合蛋白 1(HPCAL1)参与多种癌症类型的发展。然而,我们对其在胆管癌(CCA)中的作用的了解仍然有限。
使用两个微阵列数据集筛选与 CCA 发展相关的差异表达基因(DEG)。整合癌症基因组图谱(TCGA)/基因表达综合数据库(GEO)以确定 DEG 在 CCA 中的预后意义。首先探索临床特征与 HPCAL1 表达水平的关联,以评估 CCA 的临床特征。分析验证队列中 HPCAL1 过表达的预后价值,随后对 HPCAL1 进行基因本体论(GO)术语分析和京都基因与基因组百科全书(KEGG)通路分析。
从两个基于微阵列的筛选中检测到 3 个上调基因和 10 个下调基因。使用 TCGA/GEO 整合数据库和我们的数据库验证了 HPCAL1 高表达是 CCA 不良预后的因素。单因素和多因素分析以及 Kaplan-Meier 生存分析表明,HPCAL1 高表达是影响 CCA 患者总生存期和无复发生存期的独立因素。HPCAL1 高表达与癌症抗原 125(CA-125)水平、肿瘤数量、淋巴结浸润和 TNM 分期显著相关。GO 术语和 KEGG 通路富集分析表明,HPCAL1 高表达参与了关键的生物学过程和分子途径,包括宿主共生过程的调节、网格蛋白外套、肌动蛋白结合和 Rap1 信号通路。
在本研究中,HPCAL1 在 CCA 中富集,具有在识别预后不良的 CCA 患者方面的应用潜力。